|
Marijuana Abuse
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Marijuana (hereafter "tetrahydrocannabinol [THC]") use has been associated with liver fibrosis progression in retrospective analyses of patients with chronic hepatitis C (HCV).
|
27225241 |
2016 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cannabis resin then circulating contained approximately equal ratios of THC and cannabidiol (CBD), whereas sinsemilla was almost devoid of CBD.
|
29441730 |
2018 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
THC concentrations were consistent with the clinical state but not with the known pharmacokinetic properties of cannabis nor of intraperitoneal absorption.
|
29317112 |
2018 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
A 100 μg/L or higher concentration of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THC-COOH) in blood serum is generally assumed to be associated with regular and/or heavy use of cannabis.
|
30193411 |
2019 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
A double-blind, randomized, placebo-controlled crossover design was used to investigate the symptomatic effects of acute intravenous administration of ∆9-THC (1.19 mg/2 mL) in 16 healthy participants (seven males) with modest previous cannabis exposure.
|
31027219 |
2019 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
A molecularly imprinted polymer (MIP) selective for cannabinoids [Δ<sup>9</sup>-tetrahydrocannabinol (Δ9-THC), 11-nor-9-carboxy-Δ<sup>9</sup>-tetrahydrocannabinol (Δ9-THC-COOH), and 11-hydroxy-Δ<sup>9</sup>-tetrahydrocannabinol (Δ9-THC-OH)] has been synthesized, fully characterized, and applied to the assessment of plasma and urine analysis of marijuana abuse by high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS).
|
27815614 |
2017 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
A number of elements are responsible for the increased complications of cannabis use, including the increase in the potency of cannabis and an evolution in the ratio between the two primary components, Δ<sup>9</sup>-tetrahydrocannabinol (Δ<sup>9</sup>-THC) and cannabidiol (toward a higher proportion of Δ<sup>9</sup>-THC), Synthetic cannabinoid (SC) use has rapidly progressed over the last few years, primarily among frequent cannabis users, because SCs provide similar psychoactive effects to cannabis.
|
29302228 |
2017 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
A positive urine drug screen for tetrahydocannabinol (THC+ status), the principal psychoactive constituent in cannabis, was associated with worse WM performance and differential brain response in areas previously linked to WM performance.
|
30644440 |
2019 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, we addressed the effects of OEA on the association of alcohol and cannabis, a frequent combination in human alcohol addicts, and whose long-term effects are far from being understood.To this end, OEA (10 mg/kg/day, i.p.) was pharmacologically administered for 5 days/week in a preclinical model of adolescent rats with binge-like consumption (1 day/week) of ethanol (3 g/kg, i.g.) combined or not with acute administrations of Δ<sup>9</sup>-THC (5 mg/kg, i.p.) for 5 weeks.
|
31068789 |
2019 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Adolescent rats of both sexes were exposed to either cannabis smoke from postnatal days (P) 29-49 or ascending doses of THC from P35-45.
|
31044291 |
2019 |
|
Marijuana Abuse
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Air samples collected inside cannabis houses showed no detectable THC.
|
28412574 |
2017 |
|
Marijuana Abuse
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Benzodiazepines and related drugs were found in 57% of the drug-positive drivers, stimulants in 51%, cannabis (tetrahydrocannabinol, THC) in 34%, and opioids in 18%.
|
28942374 |
2017 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cocaine, heroin and methamphetamine purities were higher than their mean values estimated for the Italian and European market, while THC content in cannabis seizures was unexpectedly below the European mean values.
|
29408729 |
2018 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Conclusions Findings reveal that 9-THC contributes the most to cannabis psychoactivity.
|
28492950 |
2018 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Consistent 9-THC-content in joints lead to a SJU of 7mg of 9-THC, the integer number closest to the median values shared by both cannabis types.
|
28531767 |
2017 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Current cannabis use was evaluated by asking "In the past two weeks, have you used marijuana (including THC and/or CBD)?" and cannabis type used was assessed by asking "What do you primarily use THC, CBD, or both?".
|
31251769 |
2019 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Disparate findings and reports related to effects of cannabis consumption reflect differential relative concentration of Δ<sup>9</sup>-THC and CBD.
|
28501518 |
2017 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
During each 12-day dronabinol maintenance phase, participants were allowed to self-administer smoked cannabis containing <1% THC (placebo) or 5.7% THC (active) under forced-choice (drug vs. money) or progressive ratio conditions.
|
29689485 |
2018 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Exposure to marijuana advertising among users is common, especially via digital media, and is associated with medical use, heavier use, and use of novel products with higher THC concentrations (i.e., concentrates) or longer intoxication duration (i.e., edibles).
|
28365173 |
2017 |
|
Marijuana Abuse
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
First, we consider the role of human genetic factors and cannabis strain chemotypic differences in contributing to interindividual variation in the response to cannabinoids, such as THC, and review studies demonstrating that THC-induced impairments in decision-making processes are mediated by actions at prefrontal CB<sub>1</sub> receptors.
|
27639448 |
2017 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
For the >10/>10 genotype, there was a significant decrease of P300 amplitude as well as a significant prolongation of P300 latency under pure Δ(9)-THC but not under cannabis extract.
|
21513772 |
2011 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Frequent and occasional cannabis smokers were recruited as participants for four dosing sessions including one active (6.9% Δ<sup>9</sup> -tetrahydrocannabinol, THC) or placebo cannabis-containing brownie, followed by one active or placebo cigarette, or one active or placebo vaporized cannabis dose.
|
27647820 |
2017 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
From these results and concomitant behavioral studies, we conclude that social dysfunctions resulting from excessive intake of ∆9-THC in the increasingly available marijuana products used by male teens may largely reflect circuit defects in PL-PFC networks communicating through endocannabinoid-regulated NMDA receptors.
|
31323660 |
2020 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
Healthy cannabis smokers (N = 18) were administered oxycodone (0, 2.5, and 5.0 mg, PO) with smoked cannabis (0.0, 5.6% Δ<sup>9</sup> tetrahydrocannabinol [THC]) and analgesia was assessed using the Cold-Pressor Test (CPT).
|
29463913 |
2018 |
|
Marijuana Abuse
|
0.100 |
Biomarker
|
disease |
BEFREE |
In order to study whether the nicotine delivered via e-CIG acts as "a gateway drug" to the use of cannabis, we analysed the behavioural and molecular effects of 7 weeks' pre-exposure to air (AIR), e-CIGs or CIGs on addiction-related conditioned place preference (CPP) in mice using a sub-threshold (0.01 mg/kg) dose of delta-9-tetrahydrocannabinol (Δ<sup>9</sup>-THC), the principal psychoactive constituent of cannabis.
|
30773388 |
2019 |